Teresa Otón, Mónica Fernández Castro, Lucía Silva Fernández, José Luis Andreu
{"title":"系统性红斑狼疮的生物治疗。B淋巴细胞之外还有生命吗?","authors":"Teresa Otón, Mónica Fernández Castro, Lucía Silva Fernández, José Luis Andreu","doi":"10.1016/j.semreu.2010.08.001","DOIUrl":null,"url":null,"abstract":"<div><p>Current treatment options for systemic lupus erythematosus (SLE) fail to control all the manifestations of the disease or fully prevent flares. The most extensively studied biological therapies are directed against B cells, although other biological targets have also been explored. Biological agents against tumor necrosis factor-alfa differ in their efficacy and have been associated with the generation of antinuclear and anti-dsDNA antibodies. Anti-interleukin-10 and anti-interleukin-6 agents have also been studied, with encouraging results. Abatacept, which has been approved in rheumatoid arthritis, has not shown efficacy in placebo-controlled clinical trials.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 50-52"},"PeriodicalIF":0.0000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.08.001","citationCount":"5","resultStr":"{\"title\":\"Terapia biológica en el lupus eritematoso sistémico. ¿Hay vida más allá del linfocito B?\",\"authors\":\"Teresa Otón, Mónica Fernández Castro, Lucía Silva Fernández, José Luis Andreu\",\"doi\":\"10.1016/j.semreu.2010.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Current treatment options for systemic lupus erythematosus (SLE) fail to control all the manifestations of the disease or fully prevent flares. The most extensively studied biological therapies are directed against B cells, although other biological targets have also been explored. Biological agents against tumor necrosis factor-alfa differ in their efficacy and have been associated with the generation of antinuclear and anti-dsDNA antibodies. Anti-interleukin-10 and anti-interleukin-6 agents have also been studied, with encouraging results. Abatacept, which has been approved in rheumatoid arthritis, has not shown efficacy in placebo-controlled clinical trials.</p></div>\",\"PeriodicalId\":101152,\"journal\":{\"name\":\"Seminarios de la Fundación Espa?ola de Reumatología\",\"volume\":\"12 2\",\"pages\":\"Pages 50-52\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.semreu.2010.08.001\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminarios de la Fundación Espa?ola de Reumatología\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S157735661100008X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminarios de la Fundación Espa?ola de Reumatología","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S157735661100008X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Terapia biológica en el lupus eritematoso sistémico. ¿Hay vida más allá del linfocito B?
Current treatment options for systemic lupus erythematosus (SLE) fail to control all the manifestations of the disease or fully prevent flares. The most extensively studied biological therapies are directed against B cells, although other biological targets have also been explored. Biological agents against tumor necrosis factor-alfa differ in their efficacy and have been associated with the generation of antinuclear and anti-dsDNA antibodies. Anti-interleukin-10 and anti-interleukin-6 agents have also been studied, with encouraging results. Abatacept, which has been approved in rheumatoid arthritis, has not shown efficacy in placebo-controlled clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
